Distribution of VAF throughout the spectrum of clinical phenotypes. (A) Distribution of VAFs in individuals with CHIP (n = 70); (B) in individuals with unexplained anemia and clonal hematopoiesis (CH-AoE; n = 49); (C) in patients with CCUS (n = 87); and (D) in patients with MN (n = 518). For the purpose of this analysis, maximum VAF was analyzed in patients harboring ≥2 mutations.